Posted by Michael Wonder on 12 Oct 2020
SMC accepts Bavencio (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma
12 October 2020 - Merck and Pfizer announced today that the Scottish Medicines Consortium has accepted the immunotherapy Bavencio (avelumab) for use within NHS Scotland in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma.
The JAVELIN Renal 101 study demonstrated that avelumab in combination with axitinib met the primary endpoint of significantly longer progression-free survival in patients with PD-L1-positive clear cell advanced renal cell carcinoma, compared to patients who received sunitinib.
